Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2023 May 3;76(9):1604-1612.
doi: 10.1093/cid/ciad009.

Defining the Optimal Duration of Therapy for Hospitalized Patients With Complicated Urinary Tract Infections and Associated Bacteremia

Affiliations
Observational Study

Defining the Optimal Duration of Therapy for Hospitalized Patients With Complicated Urinary Tract Infections and Associated Bacteremia

John McAteer et al. Clin Infect Dis. .

Abstract

Background: Limited data are available to guide effective antibiotic durations for hospitalized patients with complicated urinary tract infections (cUTIs).

Methods: We conducted an observational study of patients ≥18 years at 24 US hospitals to identify the optimal treatment duration for patients with cUTI. To increase the likelihood patients experienced true infection, eligibility was limited to those with associated bacteremia. Propensity scores were generated for an inverse probability of treatment weighted analysis. The primary outcome was recurrent infection with the same species ≤30 days of completing therapy.

Results: 1099 patients met eligibility criteria and received 7 (n = 265), 10 (n = 382), or 14 (n = 452) days of therapy. There was no difference in the odds of recurrent infection for patients receiving 10 days and those receiving 14 days of therapy (aOR: .99; 95% CI: .52-1.87). Increased odds of recurrence was observed in patients receiving 7 days versus 14 days of treatment (aOR: 2.54; 95% CI: 1.40-4.60). When limiting the 7-day versus 14-day analysis to the 627 patients who remained on intravenous beta-lactam therapy or were transitioned to highly bioavailable oral agents, differences in outcomes no longer persisted (aOR: .76; 95% CI: .38-1.52). Of 76 patients with recurrent infections, 2 (11%), 2 (10%), and 10 (36%) in the 7-, 10-, and 14-day groups, respectively, had drug-resistant infections (P = .10).

Conclusions: Seven days of antibiotics appears effective for hospitalized patients with cUTI when antibiotics with comparable intravenous and oral bioavailability are administered; 10 days may be needed for all other patients.

Keywords: E. coli; UTI; antibiotics; duration; gram-negative bacteremia.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. S. E. C. reports receiving personal fees from Basilea and Theravance, outside of the submitted work, including participation on a Data Safety Monitoring Board or Advisory Board for Debiopharm. E. L. H. reports consulting fees from Wolters-Kluwer (Lexi-Comp). All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Overall cohort. Abbreviations: CFU, colony-forming units; UTI, urinary tract infection.
Figure 2.
Figure 2.
Standardized mean differences across variables for patients receiving 10 days versus 14 days of antibiotics for cUTI. Abbreviations: BMI, body mass index; ESBL, extended-spectrum beta-lactamase; ICU, intensive care unit.

Comment in

Similar articles

Cited by

References

    1. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol 2015; 13:269–84. - PMC - PubMed
    1. Hooton TM, Bradley SF, Cardenas DD, et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:625–63. - PubMed
    1. Tenney J, Hudson N, Alnifaidy H, Li JTC, Fung KH. Risk factors for acquiring multidrug-resistant organisms in urinary tract infections: a systematic literature review. Saudi Pharm J 2018; 26:678–84. - PMC - PubMed
    1. Drekonja DM, Trautner B, Amundson C, Kuskowski M, Johnson JR. Effect of 7 vs 14 days of antibiotic therapy on resolution of symptoms among afebrile men with urinary tract infection: a randomized clinical trial. JAMA 2021; 326:324–31. - PMC - PubMed
    1. Heil EL, Bork JT, Abbo LM, et al. . Optimizing the management of uncomplicated gram-negative bloodstream infections: consensus guidance using a modified Delphi process. Open Forum Infect Dis 2021; 8:ofab434. - PMC - PubMed

Publication types

Substances